Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
Keryx Biopharmaceuticals (KERX) PT Rasied to $7 at Maxim Group Following Positive Study
-
Keryx Biopharmaceuticals (KERX) Bullish Stance Reiterated at Maxim Group Following Auryxia Publications
-
Keryx Biopharma (KERX) Prices 9.17M Common Offering at $12/Share
-
Keryx Biopharmaceuticals, Inc. Announces Pricing of $110 Million Public Offering of Common Stock
-
Keryx Biopharma (KERX) Price Target Raised to $32 at Maxim
-
Unusual 11 Mid-Day Movers 9/8: (RADA) (MGAM) (BKYF) Higher; (VII) (ESYS) (DGLY) Lower
-
Keryx Biopharma (KERX) Ramps on Positive Sentiment Ahead of Sept 7 PDUFA Date
-
Keryx Biopharmaceuticals (KERX) a Buy Ahead of PDUFA Date, Maxim Group Said
-
Keryx Biopharmaceuticals (KERX) Target Lifted to $25 at Maxim Group
-
Keryx Biopharma (KERX) Prices 6.9M Offering at $14.50/Share
-
StreetInsider.com Pre-Open Movers 6/19: (PLX) (CYTK) (ADBE) Higher; (OSH) (VNDA) (TTEK) Lower (more...)
-
Keryx Biopharma (KERX) Prices 8.23M Offering at $8.49/Share
-
StreetInsider.com Pre-Open Movers 12/13: (BBY) (CLWR) (SAM) Higher; (HRG) (LXK) (RBC) Lower (more...)
-
Maxim Group Starts Keryx Biopharmaceuticals (KERX) at Buy

